DOCKET NO.: 48378-0003-00-US (229108)

**Application No.:** 10/621,711

Official Action Dated September 26, 2007

This listing of claims will replace all prior versions, and listings, of claims in the application.

**PATENT** 

**Listing of Claims:** 

1 - 162. (Canceled)

- layer and an adhesive polymer matrix containing progestin and estrogen hormones to be transdermally delivered affixed to the backing layer, wherein the adhesive polymer matrix comprises an adhesive polymer, a humectant, the progestin, the estrogen, and up to about 30% by weight of a combination of skin permeation enhancing agents comprising dimethyl sulfoxide, a fatty (C<sub>8</sub>-C<sub>20</sub>) alcohol ester of lactic acid, a lower (C<sub>1</sub>-C<sub>4</sub>) alkyl ester of lactic acid, and capric acid, wherein the capric acid is present in an amount between about 3% and about 9% by weight of the adhesive polymer matrix.
- 164. (Previously presented) The transdermal delivery system of claim 163, wherein the adhesive polymer is a polyacrylate copolymer, a polyisobutylene or a silicone adhesive.
- 165. (Previously presented) The transdermal delivery system of claim 164, wherein the polyacrylate copolymer comprises a 2-ethylhexyl acrylate monomer.
- 166. (Previously presented) The transdermal delivery system of claim 165, wherein the polyacrylate copolymer further comprises about 3 to 60% w/w vinyl acetate.
- 167. (Previously presented) The transdermal delivery system of claim 163, wherein the humectant comprises polyvinylpyrrolidone.
- 168. (Previously presented) The transdermal delivery system of claim 167, wherein the humectant comprises a polyvinylpyrrolidone copolymer.
- 169. (Previously presented) The transdermal delivery system of claim 168, wherein the humectant is a polyvinylpyrrolidone/vinyl acetate copolymer.

**DOCKET NO.:** 48378-0003-00-US (229108)

**Application No.:** 10/621,711

Official Action Dated September 26, 2007

170. (Previously presented) The transdermal delivery system of claim 169, wherein the polyvinylpyrrolidone is formulated in an amount of about 60% w/w and the vinyl acetate is formulated in an amount of about 40% w/w in the polyvinylpyrrolidone/vinyl acetate copolymer.

**PATENT** 

- 171. (Previously presented) The transdermal delivery system of claim 163, wherein the fatty alcohol ester of lactic acid is lauryl lactate.
- 172. (Previously presented) The transdermal delivery system of claim 163, wherein the lower alkyl ester of lactic acid is ethyl lactate.
- 173. (Previously presented) The transdermal delivery system of claim 163, wherein the progestin is levonorgestrel.
- 174. (Previously presented) The transdermal delivery system of claim 163, wherein the estrogen is ethinyl estradiol or 17  $\beta$ -estradiol.
- 175. (Previously presented) The transdermal delivery system of claim 173, which, when applied to the skin of a human, once each week, consecutively over a period of three or more weeks, deliver *in vivo* an average serum concentration of over 1000 pg/ml of levonorgestrel.
- 176. (Previously presented) The transdermal delivery system of claim 163, wherein the adhesive polymer matrix comprises more than 10% and less than about 30% by weight of the combination of skin permeation enhancing agents.
- 177. (Previously presented) The transdermal delivery system of claim 163, wherein the adhesive polymer matrix comprises about 18% to about 30% by weight of the combination of skin permeation enhancing agents.

**DOCKET NO.:** 48378-0003-00-US (229108)

**Application No.:** 10/621,711

Official Action Dated September 26, 2007

178. (Previously presented) The transdermal delivery system of claim 163, wherein the adhesive polymer matrix comprises about 21% to about 27% by weight of the combination of skin permeation enhancing agents.

**PATENT** 

- 179. (Previously presented) The transdermal delivery system of claim 163, wherein the adhesive polymer matrix is formulated by combining the adhesive polymer, the humectant, the progestin, the estrogen, and about 10% to about 30% by weight of the combination of skin permeation enhancing agents.
- 180. (Previously presented) The transdermal delivery system of claim 163, wherein the adhesive polymer matrix is formulated by combining the adhesive polymer, the humectant, the progestin, the estrogen, and about 13% to about 27% by weight of the combination of skin permeation enhancing agents.
- 181. (New) The transdermal delivery system of claim 163, wherein the capric acid is present in an amount between about 4% and about 8% by weight of the adhesive polymer matrix.
- 182. (New) The transdermal delivery system of claim 163, wherein the capric acid is present in an amount between about 5% and about 7% by weight of the adhesive polymer matrix.